Genetic Technologies Limited · ASX:GTG
Genetic Technologies — Shareholder Meeting (November 2013)
19 slides from Genetic Technologies's shareholder meeting presentation, Nov 29, 2013
Slide 1: 2013 Annual General Meeting ASX Announcement
ASX ANNOUNCEMENT 29 November 2013 2013 Annual General Meeting Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to release the attached slide show presentation which will be delivered by its Acting Chief Executive Officer, Mr. Tom Howitt, at the Company’s 2013 Annual General Meeting t
Slide 2: Acting CEO Address, Annual General Meeting
Genetic Technologies Limited Tom Howitt - Acting CEO Address Annual General Meeting Friday, 29 November 2013
Slide 3: Forward looking statements
Forward looking statements 2 This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business achievements/performanc
Slide 4: Summary - major achievements since last AGM
Summary - major achievements since last AGM • Major focus on the expansion of US operations • Significant and continuing growth in BREVAGen sample numbers received in each quarter, with 914 samples received during the September 2013 quarter • Increase in US sales force from 10 to 15 • GTG lab now ac
Slide 5: BREVAGen sample growth - performance to date
BREVAGen sample growth - performance to date 78 84 113 142 178 368 403 599 914 0 100 200 300 400 500 600 700 800 900 1000 2011/2012 - Q1 2011/2012 - Q2 2011/2012 - Q3 2011/2012 - Q4 2012/2013 - Q1 2012/2013 - Q2 2012/2013 - Q3 2012/2013 - Q4 2013/2014 - Q1 BREVAGen Quarterly Growth Launch to end of
Slide 6: New physicians - building repeat business
New physicians - building repeat business 5 0 5 10 15 20 25 2012.11 2012.12 2013.01 2013.02 2013.03 2013.04 2013.05 2013.06 2013.07 2013.08 2013.09 2013.10 13 19 15 13 10 17 23 19 18 11 19 22 New Prescribers per Month Twelve months to October 2013
Slide 7: Phenogen Sciences - expanding the team
Phenogen Sciences - expanding the team 6 SVP Sales/Marketing Western Dir of Sales Eastern Dir of Sales 7 RBMs: - Seattle - Dallas - Houston - Chicago - Southern California - Missouri/Kansas - Northern California/Nevada --------------------------- January 2014 - Colorado/Utah - MN/Nebraska 8 RBMs: -
Slide 8: US sales territories - all States covered
US sales territories - all 50 States covered • Update current map. 7
Slide 9: Marketing initiatives - building the network
Marketing initiatives - building the network • National/Regional/Local Press and Public Relations http://www.youtube.com/watch?v=VcyYFzeTFts • October: “Accent Health” broadcast network http://www.youtube.com/watch?v=w_nrvmP7gZg • Recent KOL/Speaker “Ambassador” Summit • Professional Conferences • P
Slide 10: KOL/Speakers Summit - to November 2013
KOL/Speakers Summit - 8 to 10 November 2013 • Rick Frieder, MD, Consulting Chief Medical Officer; Pat McNamara, Medical speaker consultant and trainer; Courtney Tate, MBA, CGC, Phenogen Sciences, Director of Marketing • 19 (of 23) Phenogen National Speakers attended • Unified scientific and clinical
Slide 11: Professional conferences - spreading the story
Professional conferences - spreading the story • ACOG District 7 Regional Meeting • Breast Cancer Challenge Conference • Multidisciplinary Breast Care Conference • Boca Raton Women’s Health Symposium • ACOG Districts 5, 6, 8, and 9 Regional Meeting • North American Menopause Society • Mid-Atlantic W
Slide 12: Patient advocacy - Cyndi Pierre
Patient advocacy - Cyndi Pierre http://www.youtube.com/watch?v=w_nrvmP7gZg “BREVAGen saved my life” 11
Slide 13: Product development - new markets and tests
Product development - new markets and tests BREVAGen 1.0: 7-SNP assay, Caucasian-only • Indication is limiting, Caucasian population in the US = 62% only • Recent advances in genetics need to be included Within next 6 months: develop/launch BREVAGen 2.0 • Collaborators have been identified and relat
Slide 14: Reimbursement - a key focus moving forward
Reimbursement - a key focus moving forward • From 1 January 2013: ‘Miscellaneous’ CPT code vs. code stack • Denials and follow-on appeals have increased, but with strong PPO contracting and increased list price, average reimbursement for closed cases has increased overall • Recent meeting held with
Slide 15: Licensing - continuing to extract value
Licensing - continuing to extract value • Seven new licenses granted, taking the total to more than 77 • More than $73 million generated from licensing to date • US assertion program continues in earnest, with 10 cases of infringement underway, including three against Big Pharma • New assertion case
Slide 16: Heritage businesses - steady cash flow
Heritage businesses - steady cash flow • Australian sales continue to exceed budget • Maintains technical capability in laboratory • Spreads overhead expenses across broader operating base • Growth opportunities exist from new tests and markets Gen Tech Lab146.jpg
Slide 17: Other assets - commercialisation underway
Other assets - commercialisation underway ImmunAid • Second round fundraising at $5.00 per share has commenced • GTG retains 4.5 million shares and is 40+% major shareholder • Further trials of ImmunAid technology being planned Gtech International • Acquisition of Simavita to be completed by Christm
Slide 18: Key objectives for 2014 financial year
Key objectives for 2014 financial year • Maintain focus on expansion of US operations • Increase US sales force to cover all major US sales territories • Complete and launch “second generation” BREVAGen test to improve performance and drive market acceptance in the US • Broaden available ethnicities
Slide 19: Thank you - any questions?
Thank you - any question? Tom Howitt Acting CEO Genetic Technologies Limited Phone +61 3 8412 7000 Email info@gtglabs.com
Genetic Technologies — Shareholder Meeting (November 2013) on 6ix